E N D
1. Bringing AWS Treatment Into Focus Paolo B. DePetrillo, M.D.
Mark K. McDonough, M Ed.
3. Why no Protocol? AWS is dynamic and therapy should be dynamic
AWS symptoms vary widely from patient to patient
some factors: age, gender, medical and psychiatric co-morbidities, history of previous withdrawal, other drug use
Response to treatment is also variable
it is important to consider each symptom cluster independently.
following a rigid medication protocol results in some patients receiving agents they do not need, and leaves others with uncontrolled symptoms
4. General Scheme for Use of Type Indicator in AWS 1. Assess patient with TI
2. Prioritize and treat symptoms
3. Repeat 1 and 2 until target symptoms have resolved
5. Dynamic Individualized Therapy Dynamic
patient is evaluated for treatment response before additional therapy is given
Individualized
symptom clusters, their order of presentation, and their severity all vary widely from patient to patient
treatment is based on the emergence of specific symptom clusters over time
Therapy
to reduce each Type score
6. Dynamic Individualized Therapy in Practice Patient is evaluated for presence of symptom clusters (Types A, B, and C) with the Type Indicator
Therapy is ordered for the treatment of specific symptoms present
Patient is re-evaluated with the Type Indicator
Therapy is adjusted based on response to prior therapy
8. Benzodiazepines in AWS Treatment Benzodiazepines are useful primarily for treating the least medically serious AWS symptoms (Type A)
Benzodiazepines have never been proven effective for the control of severe hypertension in AWS, nor in any other context
There is no evidence that treatment with benzodiazepines prevents the emergence of AWS delirium
Benzodiazepines have been shown to be associated with delirium and cognitive disruption.
9. Therapy of Type A Withdrawal Therapeutic objectives
Treat until patient is alert or easily aroused but has no Type A symptoms
Useful agents
Benzodiazepines
Anti-convulsants
Carbamazepine (Tegretol)
Valproic acid (Depakote)
10. Therapy of Type A Withdrawal When to use benzodiazepines
Type A symptoms present mild Type B symptoms
Short-acting (lorazepam) vs long-acting (diazepam or chlordiazepoxide (Librium)
Use short-acting if age > 55, liver disease
Use an alternative to benzodiazepines such as carbamazepine or valproic acid if
Patient has risk factors for atypical AWS, such as history of severe head injury, alcoholic dementia, impairment of judgement due to other psychiatric condition, delirium (unless emergent sedation required).
11. Therapy of Type A Withdrawal Common errors in use of benzodiazepine therapy of AWS
Continuing therapy with these agents to treat elevated blood pressure and/or heart rate if patient is already sedated (sleepy but arousable)
Use of these agents to treat AWS-related delirium
Commencing therapy with these agents in the presence of elevated blood alcohol levels
Use of these agents to treat disinhibited behaviors
12. Therapy of Type B Withdrawal Therapeutic objectives
Reduce Type B symptoms by attenuating the effects of elevated levels of circulating catecholamines (adrenalin) on cardiovascular system
Useful agents
Clonidine - alpha-2 adrenergic agonist which decreases central nervous system sympathetic output
Sympatholytics (directly block effects of adrenalin)
Propranolol - beta blocker
Atenolol - beta-blocker
Labetalol - alpha and beta blocker
22. References Zilker T. Alkoholentzugssyndrom und Delirium tremens. Diagnose und Therapie. MMW Fortschr Med 1999 Aug 19;141(33):26-30.
Myrick H, Brady KT, Malcolm R. Divalproex in the treatment of alcohol withdrawal. Am J Drug Alcohol Abuse. 2000 Feb;26(1):155-60.
Tiecks FP; Einhaupl KM. Behandlungsalternativen des Alkoholdelirs. [Treatment alternatives of alcohol withdrawal delirium] Nervenarzt 1994 Apr;65(4):213-9.
Isbell H, Fraser HF, Wikler A, Belleville RE, Eisenman AJ. An experimental study of the etiology of Rum Fits and Delirium Tremens. Q J Stud Alc. 1955;16:1-33.
Mendelson JH, La Dou J. Experimentally induced chronic intoxication and withdrawal in alcoholics. Q J Stud Alc. 1964;Supp 2:1-39.
De Witte P. The role of neurotransmitters in alcohol dependence: animal research. Alcohol Alcohol Suppl. 1996 Mar;1:13-6.
Grobin AC, Matthews DB, Devaud LL, Morrow AL. The role of GABA(A) receptors in the acute and chronic effects of ethanol. Psychopharmacology (Berl). 1998 Sep;139(1-2):34-43.
23. More References Linnoila M. Neurotransmitters and alcoholism: methodological issues. Adv Alcohol Subst Abuse. 1988;7(3-4):17-24.
Kumari M, Ticku MK. Regulation of NMDA receptors by ethanol. Prog Drug Res. 2000;54:152-89.
Lovinger DM. 5-HT3 receptors and the neural actions of alcohols: an increasingly exciting topic. Neurochem Int. 1999 Aug;35(2):125-30.
Higley JD, Bennett AJ. Central nervous system serotonin and personality as variables contributing to excessive alcohol consumption in non-human primates. Alcohol Alcohol. 1999 May-Jun;34(3):402-18.
Koob GF, Roberts AJ, Schulteis G, Parsons LH, Heyser CJ, Hyytia P, Merlo-Pich E, Weiss F. Neurocircuitry targets in ethanol reward and dependence. Alcohol Clin Exp Res. 1998 Feb;22(1):3-9.
Fitzgerald LW, Nestler EJ. Molecular and cellular adaptations in signal transduction pathways following ethanol exposure. Clin Neurosci. 1995;3(3):165-73.
24. More Information Alcohol Withdrawal Treatment Manual
P.B. DePetrillo and M.K. McDonough
http/www.sagetalk.com/
free on-line discussion of substance abuse issues and general information on substance abuse treatment
E-mail: info@sagetalk.com